

RS2133 - Rituximab

ABO-incompatible organ transplant - INITIATION	9
ANCA associated vasculitis - INITIATION	8
ANCA associated vasculitis - CONTINUATION	8
Antibody-mediated organ transplant rejection - INITIATION	9
B-cell acute lymphoblastic leukaemia/lymphoma* - INITIATION	16
CD20+ low grade or follicular B-cell NHL - INITIATION	14
CD20+ low grade or follicular B-cell NHL - CONTINUATION	15
Chronic lymphocytic leukaemia - INITIATION	4
Chronic lymphocytic leukaemia - CONTINUATION	5
Membranous nephropathy - INITIATION	15
Membranous nephropathy - CONTINUATION	15
Neuromyelitis Optica Spectrum Disorder (NMOSD) - INITIATION	11
Neuromyelitis Optica Spectrum Disorder (NMOSD) - CONTINUATION	11
Severe Refractory Myasthenia Gravis - INITIATION	12
Severe Refractory Myasthenia Gravis - CONTINUATION	12
Severe antisynthetase syndrome - INITIATION	12
Severe antisynthetase syndrome - CONTINUATION	13
Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - INITIATION	10
Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) - CONTINUATION	10
Steroid resistant nephrotic syndrome (SRNS) - INITIATION	10
Steroid resistant nephrotic syndrome (SRNS) - CONTINUATION	11
Aggressive CD20 positive NHL - INITIATION	3
Aggressive CD20 positive NHL - CONTINUATION	4
Anti-NMDA receptor autoimmune encephalitis - INITIATION	14
Anti-NMDA receptor autoimmune encephalitis - CONTINUATION	14
Desensitisation prior to transplant - INITIATION	16
Graft versus host disease - INITIATION	13
Haemophilia with inhibitors - INITIATION	2
Haemophilia with inhibitors - CONTINUATION	2
Immune thrombocytopenic purpura (ITP) - INITIATION	6
Immune thrombocytopenic purpura (ITP) - CONTINUATION	7
Immunoglobulin G4-related disease (IgG4-RD*) - INITIATION	17
Immunoglobulin G4-related disease (IgG4-RD*) - CONTINUATION	17
Indolent, low-grade lymphomas or hairy cell leukaemia* - INITIATION	3
Indolent, low-grade lymphomas or hairy cell leukaemia* - CONTINUATION	3
Pemphigus* - INITIATION	16
Pemphigus* - CONTINUATION	17
Post-transplant - INITIATION	2
Post-transplant - CONTINUATION	2
Pure red cell aplasia (PRCA) - INITIATION	8
Pure red cell aplasia (PRCA) - CONTINUATION	8
Severe chronic inflammatory demyelinating polyneuropathy - INITIATION	13
Severe chronic inflammatory demyelinating polyneuropathy - CONTINUATION	13
Severe cold haemagglutinin disease (CHAD) - INITIATION	5
Severe cold haemagglutinin disease (CHAD) - CONTINUATION	5
Thrombotic thrombocytopenic purpura (TTP) - INITIATION	7
Thrombotic thrombocytopenic purpura (TTP) - CONTINUATION	7
Treatment refractory systemic lupus erythematosus (SLE) - INITIATION	9
Treatment refractory systemic lupus erythematosus (SLE) - CONTINUATION	9
Warm autoimmune haemolytic anaemia (warm AIHA) - INITIATION	6
Warm autoimmune haemolytic anaemia (warm AIHA) - CONTINUATION	6

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo)

INITIATION – haemophilia with inhibitors

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has mild congenital haemophilia complicated by inhibitors
or
☐ Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy
or
☐ Patient has acquired haemophilia

CONTINUATION – haemophilia with inhibitors

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient was previously treated with rituximab for haemophilia with inhibitors
and
☐ An initial response lasting at least 12 months was demonstrated
and
☐ Patient now requires repeat treatment

INITIATION – post-transplant

Prerequisites (tick boxes where appropriate)

- ☐ The patient has B-cell post-transplant lymphoproliferative disorder*
and
☐ To be used for a maximum of 8 treatment cycles

Note: Indications marked with * are unapproved indications.

CONTINUATION – post-transplant

Prerequisites (tick boxes where appropriate)

- ☐ The patient has had a rituximab treatment-free interval of 12 months or more
and
☐ The patient has B-cell post-transplant lymphoproliferative disorder*
and
☐ To be used for no more than 6 treatment cycles

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy
and
☐ To be used for a maximum of 6 treatment cycles

or

- ☐ The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy
and
☐ To be used for a maximum of 6 treatment cycles

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

CONTINUATION – indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has had a rituximab treatment-free interval of 12 months or more
and
☐ The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy
and
☐ To be used for no more than 6 treatment cycles

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

INITIATION – aggressive CD20 positive NHL

Prerequisites (tick boxes where appropriate)

- ☐ The patient has treatment naive aggressive CD20 positive NHL
and
☐ To be used with a multi-agent chemotherapy regimen given with curative intent
and
☐ To be used for a maximum of 8 treatment cycles

or

- ☐ The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy
and
☐ To be used for a maximum of 6 treatment cycles

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – aggressive CD20 positive NHL

Prerequisites (tick boxes where appropriate)

- ☐ The patient has had a rituximab treatment-free interval of 12 months or more
and
☐ The patient has relapsed refractory/aggressive CD20 positive NHL
and
☐ To be used with a multi-agent chemotherapy regimen given with curative intent
and
☐ To be used for a maximum of 4 treatment cycles

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

INITIATION – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment
and
☐ The patient is rituximab treatment naive
or
☐ The patient is chemotherapy treatment naive
or
☐ The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment
and
☐ The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy
or
☐ The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax
and
☐ The patient has good performance status
and
☐ The patient does not have chromosome 17p deletion CLL
or
☐ Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia
and
☐ Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles
and
☐ It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient's disease has relapsed and rituximab treatment is to be used in combination with funded venetoclax
- or
- ☐ The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL
- and
- ☐ The patient has had an interval of 36 months or more since commencement of initial rituximab treatment
- and
- ☐ The patient does not have chromosome 17p deletion CLL
- and
- ☐ It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine
- and
- ☐ Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

INITIATION – severe cold haemagglutinin disease (CHAD)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
- and
- ☐ Patient has cold haemagglutinin disease*
- and
- ☐ Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms
- and
- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

CONTINUATION – severe cold haemagglutinin disease (CHAD)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
- and
- ☐ Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned
- or
- ☐ Patient was previously treated with rituximab for severe cold haemagglutinin disease*
- and
- ☐ An initial response lasting at least 12 months was demonstrated
- and
- ☐ Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – warm autoimmune haemolytic anaemia (warm AIHA)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has warm autoimmune haemolytic anaemia*

and

- ☐ One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin

and

- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

CONTINUATION – warm autoimmune haemolytic anaemia (warm AIHA)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned

or

- ☐ Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*
- and
- ☐ An initial response lasting at least 12 months was demonstrated
- and
- ☐ Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

INITIATION – immune thrombocytopenic purpura (ITP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre
- or
- ☐ Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding

and

- ☐ Treatment with steroids and splenectomy have been ineffective
- or
- ☐ Treatment with steroids has been ineffective and splenectomy is an absolute contraindication
- or
- ☐ Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy)

and

- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – immune thrombocytopenic purpura (ITP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned

or

- ☐ Patient was previously treated with rituximab for immune thrombocytopenic purpura*
and
☐ An initial response lasting at least 12 months was demonstrated
and
☐ Patient now requires repeat treatment

Note: Indications marked with * are unapproved indications.

INITIATION – thrombotic thrombocytopenic purpura (TTP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

and

- ☐ Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange
or
☐ Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology

Note: Indications marked with * are unapproved indications.

CONTINUATION – thrombotic thrombocytopenic purpura (TTP)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*
and
☐ An initial response lasting at least 12 months was demonstrated
and
☐ Patient now requires repeat treatment
and
☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – pure red cell aplasia (PRCA)

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

☐ Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder

Note: Indications marked with * are unapproved indications.

CONTINUATION – pure red cell aplasia (PRCA)

Re-assessment required after 6 weeks

Prerequisites (tick box where appropriate)

☐ Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

☐ Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months

Note: Indications marked with * are unapproved indications.

INITIATION – ANCA associated vasculitis

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

☐ Patient has been diagnosed with ANCA associated vasculitis*

and

☐ The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks

and

☐ Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months

or

☐ Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g

or

☐ Cyclophosphamide and methotrexate are contraindicated

or

☐ Patient is a female of child-bearing potential

or

☐ Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy

Note: Indications marked with * are unapproved indications.

CONTINUATION – ANCA associated vasculitis

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

☐ Patient has been diagnosed with ANCA associated vasculitis*

and

☐ Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis

and

☐ The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - continued

INITIATION – treatment refractory systemic lupus erythematosus (SLE)

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist or nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The patient has severe, immediately life- or organ-threatening SLE*
- and
- ☐ The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg
- and
- ☐ The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated
- and
- ☐ Maximum of four 1000 mg infusions of rituximab

Note: Indications marked with * are unapproved indications.

CONTINUATION – treatment refractory systemic lupus erythematosus (SLE)

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist or nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment
- and
- ☐ The disease has subsequently relapsed
- and
- ☐ Maximum of two 1000 mg infusions of rituximab

Note: Indications marked with * are unapproved indications.

INITIATION – Antibody-mediated organ transplant rejection

Prerequisites (tick box where appropriate)

- ☐ Patient has been diagnosed with antibody-mediated organ transplant rejection*

Note: Indications marked with * are unapproved indications.

INITIATION – ABO-incompatible organ transplant

Prerequisites (tick box where appropriate)

- ☐ Patient is to undergo an ABO-incompatible solid organ transplant*

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient is a child with SDNS* or FRNS*
- and ☐ Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity
- and ☐ Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects
- and ☐ Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses
- and ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

CONTINUATION – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient who was previously treated with rituximab for nephrotic syndrome*
- and ☐ Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment
- and ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

INITIATION – Steroid resistant nephrotic syndrome (SRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective
- and ☐ Treatment with tacrolimus for at least 3 months has been ineffective
- and ☐ Genetic causes of nephrotic syndrome have been excluded
- and ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – Steroid resistant nephrotic syndrome (SRNS)

Re-assessment required after 8 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a nephrologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient who was previously treated with rituximab for nephrotic syndrome*

and

- ☐ Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment

and

- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note: Indications marked with a * are unapproved indications.

INITIATION – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks

and

- ☐ The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD)

or

- ☐ The patient has experienced a breakthrough attack of NMOSD

and

- ☐ The patient is receiving treatment with mycophenolate

and

- ☐ The patients is receiving treatment with corticosteroids

CONTINUATION – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- ☐ One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks

and

- ☐ The patients has responded to the most recent course of rituximab

and

- ☐ The patient has not received rituximab in the previous 6 months

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – Severe Refractory Myasthenia Gravis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

and

- ☐ Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective

or

- ☐ Treatment with at least one other immunosuppressant for a period of at least 12 months

and

- ☐ Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects

CONTINUATION – Severe Refractory Myasthenia Gravis

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

and

- ☐ An initial response lasting at least 12 months was demonstrated

and

- ☐ The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months

or

- ☐ The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months

and

- ☐ Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects

INITIATION – Severe antisynthetase syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient has confirmed antisynthetase syndrome

and

- ☐ Patient has severe, immediately life or organ threatening disease, including interstitial lung disease

and

- ☐ Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not been effective at controlling active disease

or

- ☐ Rapid treatment is required due to life threatening complications

and

- ☐ Maximum of four 1,000 mg infusions of rituximab

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – Severe antisynthetase syndrome

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function
- and ☐ The patient has not received rituximab in the previous 6 months
- and ☐ Maximum of two cycles of 2 × 1,000 mg infusions of rituximab given two weeks apart

INITIATION – graft versus host disease

Prerequisites (tick boxes where appropriate)

- ☐ Patient has refractory graft versus host disease following transplant
- and ☐ Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not been effective at controlling active disease
- and ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

INITIATION – severe chronic inflammatory demyelinating polyneuropathy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
- and ☐ Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD)
- and ☐ Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease
- and ☐ At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease
- or ☐ Rapid treatment is required due to life threatening complications
- and ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

CONTINUATION – severe chronic inflammatory demyelinating polyneuropathy

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline
- and ☐ The patient has not received rituximab in the previous 6 months
- and ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – anti-NMDA receptor autoimmune encephalitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has severe anti-NMDA receptor autoimmune encephalitis

and

- ☐ Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease

and

- ☐ At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease

or

- ☐ Rapid treatment is required due to life threatening complications

and

- ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

CONTINUATION – anti-NMDA receptor autoimmune encephalitis

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function

and

- ☐ The patient has not received rituximab in the previous 6 months

and

- ☐ The patient has experienced a relapse and now requires further treatment

and

- ☐ One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart

INITIATION – CD20+ low grade or follicular B-cell NHL

Re-assessment required after 9 months

Prerequisites (tick boxes where appropriate)

- ☐ The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy

and

- ☐ To be used for a maximum of 6 treatment cycles

or

- ☐ The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy

and

- ☐ To be used for a maximum of 6 treatment cycles

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – CD20+ low grade or follicular B-cell NHL

Re-assessment required after 24 months

Prerequisites (tick boxes where appropriate)

- ☐ Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy
- and
- ☐ Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m² every 8 weeks (maximum of 12 cycles)

INITIATION – Membranous nephropathy

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Patient has biopsy-proven primary/idiopathic membranous nephropathy*
- or
- ☐ Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m²
- and
- ☐ Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note)
- and
- ☐ The total rituximab dose would not exceed the equivalent of 375mg/m² of body surface area per week for a total of 4 weeks

CONTINUATION – Membranous nephropathy

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Patient was previously treated with rituximab for membranous nephropathy*
- and
- ☐ Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment
- or
- ☐ Patient achieved partial response to treatment and requires repeat treatment (see Note)
- and
- ☐ The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks

Note:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

INITIATION – B-cell acute lymphoblastic leukaemia/lymphoma*

Re-assessment required after 2 years

Prerequisites (tick boxes where appropriate)

- ☐ Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*
and
☐ Treatment must be in combination with an intensive chemotherapy protocol with curative intent
and
☐ The total rituximab dose would not exceed the equivalent of 375 mg/m² per dose for a maximum of 18 doses

Note: Indications marked with * are unapproved indications.

INITIATION – desensitisation prior to transplant

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Patient requires desensitisation prior to mismatched allogenic stem cell transplant*
and
☐ Patient would receive no more than two doses at 375 mg/m² of body-surface area

Note: Indications marked with * are unapproved indications.

INITIATION – pemphigus*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a dermatologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
and
☐ Patient has severe rapidly progressive pemphigus
and
☐ Is used in combination with systemic corticosteroids (20 mg/day)
and
☐ Skin involvement is at least 5% body surface area
or
☐ Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions
or
☐ Involvement of two or more mucosal sites
or
☐ Patient has pemphigus
and
☐ Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Rituximab (Riximyo) - *continued*

CONTINUATION – pemphigus*

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a dermatologist or relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement

and

- ☐ Patient has not received rituximab in the previous 6 months

Note: Indications marked with * are unapproved indications.

INITIATION – immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 6 weeks

Prerequisites (tick boxes where appropriate)

- ☐ Patient has confirmed diagnosis of IgG4-RD*

and

- ☐ Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse

or

- ☐ Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance

and

- ☐ Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart

Note: Indications marked with * are unapproved indications.

CONTINUATION – immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed

or

- ☐ Patient is receiving maintenance treatment for IgG4-RD*

and

- ☐ Rituximab re-treatment not to be given within 6 months of previous course of treatment

and

- ☐ Maximum of two 1000 mg infusions of rituximab given two weeks apart

Note: Indications marked with * are unapproved indications.

I confirm that the above details are correct:

Signed: Date: